The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia
NCT01869049 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2016-04-20
Summary
This project was undertaken by Qilu Hospital of Shandong University and other well-known hospitals in China. In order to report the alteration on the macrophage function in the spleen tissue of primary immune thrombocytopenia (ITP).
Conditions
Sponsors & Collaborators
-
Shandong University
lead OTHER
Principal Investigators
-
Jun Peng, dr. · Qilu Hospital, Shandong University
Eligibility
- Min Age
- 15 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-11-30
- Primary Completion
- 2013-09-30
Countries
- China
Study Locations
More Related Trials
-
The Study of Different Dose Rituximab in the Treatment of ITP
NCT03258866 ·Status: COMPLETED ·Phase: PHASE4
-
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06107582 ·Status: RECRUITING
-
A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
NCT02203422 ·Status: WITHDRAWN ·Phase: PHASE3
-
rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
NCT01525836 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
NCT03443570 ·Status: UNKNOWN ·Phase: PHASE3
-
An Investigation of rhTPO With Different Frequencies in the Management of ITP
NCT02139501 ·Status: COMPLETED ·Phase: PHASE3
-
Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP
NCT04917679 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
NCT06838949 ·Status: RECRUITING ·Phase: PHASE2
-
Ultrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia
NCT07182760 ·Status: NOT_YET_RECRUITING
-
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415 ·Status: WITHDRAWN ·Phase: PHASE1
-
Biologic Characterization of Patients With ITP
NCT05694325 ·Status: RECRUITING ·Phase: NA
-
Study of Immune Thrombocytopenia Pathogenesis:
NCT02042560 ·Status: COMPLETED
-
Longitudinal Observational Study on Immune Thrombocytopenia
NCT07068425 ·Status: NOT_YET_RECRUITING
-
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
NCT01719692 ·Status: COMPLETED ·Phase: NA
-
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
NCT05998759 ·Status: RECRUITING ·Phase: PHASE2
-
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07297563 ·Status: RECRUITING ·Phase: PHASE2
-
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
NCT01317966 ·Status: WITHDRAWN
-
The Serum Lipid Profiles in ITP: a Retrospective Study
NCT05095896 ·Status: COMPLETED
-
Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura
NCT04056507 ·Status: COMPLETED
-
Evaluation of HRQoL in Adult With Immune Thrombocytopenia in China
NCT03324087 ·Status: UNKNOWN
-
A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts
NCT05583838 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
NCT01440361 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients
NCT03998059 ·Status: RECRUITING
-
Treatment of ITP With Rituximab and / or Accutane
NCT02757196 ·Status: UNKNOWN ·Phase: PHASE2
-
A 6-month Follow-up Study of Patients With Severe Fever With Thrombocytopenia Syndrome
NCT06011902 ·Status: UNKNOWN